We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

87 hedge funds and large institutions have $180M invested in Catalyst Pharmaceutical in 2015 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

684% more call options, than puts

Call options by funds: $588K | Put options by funds: $75K

150% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 14

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

32% more funds holding

Funds holding: 66 → 87 (+21)

7% more capital invested

Capital invested by funds: $168M → $180M (+$11.3M)

Holders
87
Holders Change
+21
Holders Change %
+31.82%
% of All Funds
2.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
35
Increased
24
Reduced
18
Closed
14
Calls
$588K
Puts
$75K
Net Calls
+$513K
Net Calls Change
+$466K

Top Buyers

1
Federated Hermes
Federated Hermes
Pennsylvania
+$10.3M
2
BFA
BlackRock Fund Advisors
California
+$7.14M
3
CCM
Consonance Capital Management
New York
+$2.66M
4
State Street
State Street
Massachusetts
+$2.46M
5
BIT
BlackRock Institutional Trust
California
+$2.26M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$12.4M
2
Morgan Stanley
Morgan Stanley
New York
-$1.6M
3
PA
Perceptive Advisors
New York
-$1.39M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.26M
5
BBA
Baker Bros. Advisors
New York
-$916K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
101
Tower Research Capital (TRC)
New York
– -$16.7K -4,201 -98%
1 2 3 4
5

CPRX Hedge Fund Activity: Q2 2015 in Review

87 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2015, worth a combined $180M — up 6.7% from $168M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CPRX positions and 14 closed out — a net gain of 21 holders — while 24 added to existing stakes and 18 trimmed.

The largest buyer was Federated Hermes, adding an estimated $10.3M. The largest seller was Point72 Asset Management, cutting an estimated $12.4M.

  • 87 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2015, up from 66 in Q1 2015.
  • Funds reported $180M of Catalyst Pharmaceutical stock for Q2 2015, up 6.7% quarter-over-quarter.
  • 35 funds opened new Catalyst Pharmaceutical positions in Q2 2015 and 14 closed out, a net change of +21 holders.
  • The largest Catalyst Pharmaceutical buyer in Q2 2015 was Federated Hermes, an estimated $10.3M added.
  • The largest Catalyst Pharmaceutical seller in Q2 2015 was Point72 Asset Management, an estimated $12.4M sold.

Based on aggregated 13F filings for Q2 2015.